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Abstract
Nisin, a bacteriocin and commonly used food preservative, may serve as a novel
potential therapeutic for treating head and neck squamous cell carcinoma
(HNSCC), as it induces preferential apoptosis, cell cycle arrest, and reduces cell
proliferation in HNSCC cells, compared with primary keratinocytes. Nisin also
reduces HNSCC tumorigenesis in vivo. Mechanistically, nisin exerts these effects
on HNSCC, in part, through CHAC1, a proapoptotic cation transport regula-
tor, and through a concomitant CHAC1-independent influx of extracellular cal-
cium. In addition, although CHAC1 is known as an apoptotic mediator, its
effects on cancer cell apoptosis have not been examined. Our studies are the
first to report CHAC1’s new role in promoting cancer cell apoptosis under
nisin treatment. These data support the concept that nisin decreases HNSCC
tumorigenesis in vitro and in vivo by inducing increased cell apoptosis and
decreased cell proliferation; effects that are mediated by activation of CHAC1,
increased calcium influxes, and induction of cell cycle arrest. These findings
support the use of nisin as a potentially novel therapeutic for HNSCC, and as
nisin is safe for human consumption and currently used in food preservation,
its translation into a clinical setting may be facilitated.
Introduction
Oral cancer is a leading cause of death worldwide, and oral
squamous cell carcinoma (OSCC) accounts for more than
90% of oral malignancies (http://seer.cancer.gov/statfacts),
yet survival rates for oral cancer have not improved in
decades. These disheartening statistics underscore the need
to examine its pathogenesis to help identify novel bio-
markers and modes of therapy.
This study investigated the potential use of anti-
microbial peptides (bacteriocins) as antitumor agents.
Many biological functions have been attributed to anti-
microbial peptides, including inhibition of membrane
protein synthesis, inhibition of DNA synthesis, antiviral
properties, and antitumor effects, which include induction
of apoptosis or cytotoxicity of tumor cells [1–3]. Because
of these properties, antimicrobial peptides have been
investigated as potential therapeutic drugs [4].
Our data indicate that a commonly used food preserva-
tive and bacteriocin, nisin, has antitumor potential. Nisin
is a 34-amino acid polycyclic antibacterial peptide that is
produced by fermentation of the gram-positive bacterium
Lactococcus lactis. Many antibacterial agents are effective
against similar bacterial species; however, nisin has broad-
spectrum effects, as it also inhibits gram-negative bacteria
[5]. While bacteriocins, like nisin, have been used for years
in preventing bacterial growth in foods, they have only
recently been tested for prevention of growth of cancer
cells. Nisin is not toxic to animals, is safe for human con-
sumption, and was approved for human use by the WHO
in 1969 and by the FDA in 1988. About 0.6 mg of nisin
are consumed per person per day as part of normal food
consumption (http://www.fda.gov/Food/FoodIngredients-
Packaging/GenerallyRecognizedasSafeGRAS/GRASListings/
ucm153977.htm). Therefore, development of nisin as a
cancer therapeutic can be readily pursued following dosing
determinations.
Nisin acts by altering the integrity of the cellular mem-
brane and forming short-lived pores, thereby changing the
membrane potential [6]. Nisin becomes immersed in the
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cell membrane through the cationic portions of the amino
acids extending to one side of the molecule. These cationic
portions interact with the negatively charged phospholipid
heads, while the hydrophobic portion of nisin interacts
with the membrane core [7]. Nisin’s involvement with the
membrane, therefore, mediates phospholipid reorganiza-
tion and allows for an influx of ions [6, 8]. Nisin is known
to preferentially interact with phosphatidylcholine [9].
As head and neck squamous cell carcinoma (HNSCC) cells
and primary keratinocytes differ in their lipid membrane
composition and function and response to calcium fluxes
[10–15], nisin’s ability to alter the transmembrane potential
and membrane composition of cells may lead to differential
effects on these cells. Indeed, our data support this premise
as the basis for the nisin-mediated differential apoptotic cell
death and reduced proliferation of HNSCC cells compared
to primary keratinocytes.
Although the antibacterial properties of nisin have been
used for decades in food preservation, it has only recently
been examined in altering other forms of cell growth. Apop-
tosis or programmed cell death is a natural process that
eliminates older cells. However, cancer cells are resistant to
apoptosis, and thus, there is great effort to understand the
mechanisms that regulate apoptosis in these cells. Mito-
chondria and endoplasmic reticulum begin the degradation
process of apoptosis [16]. Released cytochrome c from the
mitochondria binds to endoplasmic reticulum, causing the
release of calcium. Calcium and cytochrome c release are
key to apoptosome formation, and thereby to activation of
caspases and nucleases, which cleave substrates and DNA to
propagate apoptosis. Calcium is therefore a key regulatory
ion not only in cell death but also in cell survival pathways.
Calcium can also mediate apoptosis by altering the activa-
tion of cell surface death receptors and caspases. The role
that calcium may play in nisin-triggered cell death has not
been delineated. However, because nisin produces pores in
cell membranes that lead to a net influx of ions, such as cal-
cium, calcium may play a significant role in the induction
of apoptosis and changes in cell proliferation in cells.
Given nisin’s role as a safe bacteriocin for food preserva-
tion, and the knowledge that other bacteriocins possess pro-
apoptotic properties against cancer cells, the goals of this
study were to examine the effects and mechanisms of nisin
on HNSCC cell apoptosis and cell proliferation in vitro and
in vivo in an oral cancer mouse model. If effective, nisin
could form the basis of a novel therapeutic for HNSCC.
Methods
Cell culture
Three human HNSCC cell lines and primary human oral
keratinocytes were used for these studies. HNSCC cell line
authentication and origin was provided by their sources
and published extensively. The human HNSCC cell lines,
UM-SCC-17B, and UM-SCC-14A were provided by Tom
Carey (University of Michigan, MI). The oral SCC cell line
HSC-3 was provided by Randall Kramer (University of
California, San Francisco, CA). HNSCC cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum, 1% penicillin, and 1%
streptomycin. Primary human oral keratinocytes were
purchased from Science Cell Research Laboratories and
maintained in oral keratinocyte medium.
Assessment of intracellular calcium
concentration
Changes in intracellular calcium concentration mediated
by nisin (Sigma, St. Louis, MO) and treatment with the
calcium channel blocker, Bepridil (Sigma), were measured
with the calcium sensitive dye Fluo-4 (Fluo-4 NW
calcium assay kit, Invitrogen, Carlsbad, CA) in a multi-
detection microplate reader. After treatment with nisin
and Bepridil, Bepridil alone, nisin alone, or no treatment,
media were removed and replaced with 100 lL of Fluo-4
NW dye mix according to the manufacturer’s protocol.
The samples were excited at 494 nm and fluorescence
emission was measured at 516 nm.
Apoptosis assay
A DNA fragmentation ELISA (Roche Diagnostics, India-
napolis, IN) was used to assess cellular apoptosis follow-
ing various treatments. Specifically, this assay used
specific monoclonal antibodies directed against histones
from fragmented DNA, allowing the determination of
mono- and oligonucleosomes in the cytoplasmic fraction
of cell lysates. Briefly, cells were plated in six-well culture
plates overnight and treated with different concentrations
of nisin for 24 h. Following this incubation period, the
cells were lysed and assayed according the manufacturer’s
instructions. DNA fragmentation was evaluated by spec-
trophotometric analysis of samples within microtiter
plates using a plate reader set at 405 nm, and the values
were plotted as absorbance units.
Cell cycle analyses
Following treatment with nisin or no treatment, cells were
harvested and suspended in enzyme-free dissociation buf-
fer (Invitrogen, Carlsbad, CA). Cells were then stained by
addition of 250 lL of 50 lg/mL propidium iodide, 0.15%
Triton X-100, and 150 lg/mL RNase A before cell cycle
analysis by flow cytometry (Becton Dickinson, Franklin
Lakes, NJ).
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Gene array analyses
To examine the mechanism regulating nisin-mediated
actions on HNSCC cells, gene array analyses were
performed on nisin treated (20 lg/mL of nisin over-
night) and untreated HSC-3 cells. In all, 250 ng of total
RNA was isolated from these cells using the RNeasy
mini kit (Qiagen, Valencia, CA). Amplification and
hybridization were performed by the University of
Michigan Comprehensive Cancer Center Affymetrix and
Microarray Core Facility using the GeneChip Mouse
Genome 430 2.0 Array (Affymetrix, Santa Clara, CA).
Approximately 39,000 genes were examined with the
gene arrays, and differences greater than twofold in the
nisin-treated groups compared with untreated controls
were noted.
CHAC1 suppression and overexpression
CHAC1 human-specific siRNAs (SASI_Hs01_00146246,
SASI_Hs01_00146247, SASI_Hs01_00146249, SASI_Hs01_
00146250, SASI_Hs01_00146251; and a scrambled control;
Sigma) were transfected into HNSCC cells with HiPerFect
reagent (Qiagen) according to manufacturer’s protocols.
For stable suppression of CHAC1, CHAC1 shRNA lentivi-
ral particles (SHCLNG-NM_024111; TRCN0000154346,
TRCN0000157127, TRCN0000157739, TRCN0000158316,
and control shRNA; Sigma) were transduced into HNSCC
cells then selected in 10 lg/mL puromycin for an addi-
tional 10 days (sc-108071; Santa Cruz Biotechnology, Santa
Cruz, CA). Surviving cell colonies were picked and propa-
gated before testing for CHAC1 expression. CHAC1 cDNA
(provided by Dr. Imran Mungrue, UCLA [17]) and vector
control were transfected into HNSCC cells using Lipofecta-
mine 2000 (Invitrogren, Grand Island, NY) according to
manufacturer’s protocols. Following transfection/transduc-
tion, standard Western blotting was used to verify that sup-
pression and overexpression of CHAC1 was achieved
(CHAC1 antibody, AV42623, Sigma). Following efficient
transfection, cells were treated with nisin or untreated, then
changes in cell proliferation, apoptosis, and calcium influx
levels were assessed.
In vivo toxicity
The maximum tolerated drug doses are usually 57–75%
of the LD50 dose in mice [18]. Early safety studies
showed that oral administration of nisin in the range of
0.0125–125 lg/kg per day did not show negative side
effects on growth and tissues in rats [19]. Other studies
with higher doses of nisin (15–20 mg/kg per day) dem-
onstrated that nisin did not have adverse effect on rats
[20]. Based on the rat reproduction/chronic toxicity
study by [21], the FDA and WHO accepted the highest
dose tested in that study, 83.25 mg/kg of diet, as the
no-observed-effect-level (NOEL) and affirmed the gener-
ally recognized as safe (GRAS) status of nisin. In this
study, acute toxicity from daily administration of
150 mg/kg of nisin by oral gavage were monitored for
3 weeks in 3-week-old athymic nude mice (NCr-nu/nu
strain, NCI, Frederick, MD). Mice were monitored daily
and euthanized at the end of 3 weeks, at which time the
major organs that metabolize drugs, the liver and
kidney, were harvested and processed for histological
examination.
Oral cancer mouse model
To examine the effects of nisin, an oral cancer floor-of-
mouth mouse model was used. HNSCC cells were
injected submucosally into the floor of the mouth in mice
as previously described [22, 23]. All protocols for in vivo
studies were submitted for approval to the Committee on
the Use and Care of Animals at the University of Michi-
gan. Specifically, cells were grown to 70% confluence, sus-
pended in DMEM, mixed with an equal volume of
growth factor-reduced Matrigel basement membrane
matrix (BD Biosciences, San Jose, CA) at a final concen-
tration of 1.25 9 105/0.05 mL. Six-week-old athymic
nude mice (NCr-nu/nu strain, NCI, Frederick, MD) were
anesthetized by intraperitoneal injection of 100 mg/kg
ketamine and 10 mg/kg xylazine. A total volume of
0.05 mL of SCC cell/Matrigel suspension was injected
submucosally into the floor of the mouth. Tumor volume
was assessed weekly with digital calipers. Daily adminis-
tration of nisin or water (equal volume/control) by oral
gavage was tested using two nisin treatment regimens. A
nisin pretreatment group, where nisin administration
(200 mg/kg per day) was started 3 weeks before tumor
cell injections and continued for 3 weeks thereafter, was
used to examine whether preloading with nisin would be
efficacious. The other treatment group consisted of nisin
administration posttumor cell injection, where nisin
(200 mg/kg per day) was administered 3 weeks after ini-
tial tumor cell injections (or after tumor cell growth was
verified and palpable) and continued for 3 weeks there-
after. For CHAC1 suppression experiments, nisin
(200 mg/kg per day) was given for 3 weeks following
tumor cell injections. Following completion of nisin
administration, mice were euthanized by CO2 overdose
and cervical dislocation, and the primary tumor and kid-
ney, heart, lungs, and liver were harvested, rinsed in PBS,
and fixed overnight in 10% buffered formalin. Tissues
were paraffin-embedded, sectioned, and processed for
routine histopathological assessment with hematoxylin
and eosin staining.
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Statistical analyses
In general, values are expressed as means ± SD. Inter-
group differences were determined by two-way analysis of
variance (ANOVA) and Scheffe’s multiple-comparison
test. Individual P values for each data set are indicated
individually in each figure. For the in vivo studies, inde-
pendent t tests with unequal variances were used. All
experiments were repeated at least three times.
Results
Nisin increases apoptosis and reduces cell
proliferation in HNSCC cells
Treatment of three different HNSCC cell lines with
increasing concentrations of nisin (5, 10, 20, 40, and
80 lg/mL) induced increased levels of DNA fragmenta-
tion or apoptosis after 24 h of treatment (Fig. 1). Sig-
nificant increases in DNA fragmentation emerged in
HNSCC cells when nisin concentrations reached over
20 lg/mL and up to 80 lg/mL. In contrast, primary
oral keratinocytes did not exhibit elevated levels of
DNA fragmentation like HNSCC cells. Nisin treatment
with 80 lg/mL also reduced cell proliferation in three
HNSCC cell lines over time with significant differences
noted after 24 h of treatment. In contrast, primary oral
keratinocytes did not exhibit decreases in cell prolifera-
tion over time upon treatment with the same concen-
tration of nisin. Therefore, nisin preferentially increases
DNA fragmentation or apoptosis and decreases cell
proliferation in HNSCC cells dose- and time-
dependently.
Nisin-mediated calcium influxes and
apoptosis are blocked by a calcium channel
blocker
Nisin is known to alter the influx of ions through its
effects on membrane phospholipid reorganization [24].
To determine whether nisin’s ability to induce apopto-






















17B 80 μg/mL of Nisin
KT 80 μg/mL of Nisin
HSC 80 μg/mL of Nisin
KT 80 μg/mL of Nisin
14A 80 μg/mL of Nisin

































































































































































0.8 KT no treatment
0.0045
0
0 2 4 8 10 24 (h)
0 5 10 20 40 80
Nisin (μg/mL)
0 5 10 20 40 80
Nisin (μg/mL)
0 5 10 20 40 80
0 2 4 8 10 24
0 2 4 8 10 24 (h)
Figure 1. Nisin preferentially induces apoptosis and inhibits cell proliferation in head and neck squamous cell carcinoma (HNSCC) cells versus
primary keratinocytes. (A–C) DNA fragmentation after 24 h and (D–F) fold change in cell proliferation in HNSCC cells (UM-SCC-17B, HSC-3, and
UM-SCC-14A) after treatment with nisin as indicated. P values for each data set are indicated individually.
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alter calcium influxes in these cells, calcium influx lev-
els were measured following nisin treatment. Nisin
treatment significantly increased calcium influxes in
HNSCC cells, and treatment with a calcium channel
blocker, Bepridil, blocked the nisin-mediated calcium
influx (Fig. 2). Bepridil also blocked the nisin-mediated
DNA fragmentation or apoptosis in HNSCC cells dose-
dependently. These data indicate that nisin mediates
apoptosis in HNSCC cells via changes in calcium
influxes.
Nisin reduces HNSCC cell proliferation by
arresting cells in the G2 phase of the cell
cycle
To further explore nisin’s effects on HNSCC cell prolifer-
ation, cell cycle status was examined (Fig. 3). Treatment
of HNSCC cells with nisin induced cell cycle arrest in the
G2 phase with concomitant decreases in Cdc2 phosphory-
lation, a cell cycle checkpoint marker (Figs. 3 and S2). In
addition, in agreement with the DNA fragmentation data
(Fig. 1), nisin concomitantly increased levels/cleavage of
the apoptotic markers cPARP and active caspase-3
(Fig. S2).
CHAC1, a cation transport regulator, is
upregulated by nisin treatment
To examine the mechanism by which nisin mediates its
proapoptotic and antiproliferative effects on HNSCC cells,
gene expression arrays were used to explore potential genes
altered by nisin treatment in these cells. Using Affymetrix
gene arrays that examine over 39,000 genes, CHAC1, a
cation transport regulator and apoptosis mediator [17] was
identified as the most highly upregulated (fourfold) gene in
nisin-treated HNSCC cells compared with untreated con-
trols (Table 1). CHAC1 protein levels were also increased
in these cells upon nisin treatment as confirmed by Wes-
tern blotting (Fig. 4). Other genes that were also upregulat-
ed or downregulated by nisin treatment up to twofold were
included in Table 1. Nisin-altered genes included those in
apoptotic and cell cycle pathways, membrane physiology,
ion transport, energy and nutrient pathways, and protein
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Figure 2. Nisin-mediated calcium influxes and apoptosis are blocked by bepridil (BP), a calcium channel blocker. (A) and (B) Calcium influx and
(C) DNA fragmentation levels in UM-SCC-17B cells after treatment with nisin (80 lg/mL) and bepridil as indicated for 24 h. P values for each data
set are indicated individually.
Figure 3. Nisin induces cell cycle arrest. Cell cycle analysis of UM-SCC-17B cells after treatment with nisin (80 lg/mL) or control for 24 h.
© 2012 The Authors. Published by Blackwell Publishing Ltd. 299





















































































Figure 4. CHAC1 suppression inhibits nisin-induced DNA fragmentation. (A) Immunoblot showing CHAC1 expression in UM-SCC-17B cells after
treatment with nisin (80 lg/mL) for 24 h. b-Actin served as loading control. (B) DNA fragmentation, (C) fold change in proliferation, and
(D) calcium influx levels in UM-SCC-17B cells after transfection with CTRL siRNA or CHAC1 siRNA and treated with nisin (80 lg/mL) for 24 h.






















































































Figure 5. CHAC1 overexpression increases nisin-induced DNA fragmentation. (A) DNA fragmentation, (B) fold change in proliferation, and
(C) calcium influx levels in UM-SCC-17B cells after transfection with CHAC1 cDNA and treated with nisin (80 lg/mL) for 24 h. Inset, immunoblot
showing CHAC1 levels after transfection with CHAC1 cDNA. P values for each data set are indicated individually.
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Table 1. Gene microarray table illustrating fold change in gene expression of HNSCC cells treated with nisin compared with untreated controls.
Symbol Description Gene ontology Fold change
CHAC1 ChaC, cation transport regulator homolog 1
(Escherichia coli)
Protein binding 4.42976
PDE4C Phosphodiesterase 4C, cAMP specific
(phosphodiesterase E1 dunce homolog, Drosophila)
Signal transduction 4.29073
LGALS1 Lectin, galactoside-binding, soluble, 1 (galectin 1) Sugar binding
Regulation of apoptosis
3.64717
S100P S100 calcium-binding protein P Calcium ion binding
Calcium-dependent protein binding
3.21482
STC2 Stanniocalcin 2 Cell surface receptor linked signal transduction
Response to nutrient
3.17316




ARC Activity-regulated cytoskeleton-associated protein Membrane
Cell junction
2.35159
PYGM Phosphorylase, glycogen; muscle (McArdle syndrome,





RAB3A RAB3A, member RAS oncogene family Membrane 2.26615
TEX14 Testis expressed 14 ATP binding 2.24405
SDPR Serum deprivation response (phosphatidylserine-binding protein) Phosphatidylserine binding
Membrane fraction
2.20425




ITGAM Integrin, alpha M (complement component 3 receptor 3 subunit) Magnesium ion binding
Calcium ion binding
External side of plasma membrane
Integral to membrane
2.13638
SESN2 Sestrin 2 Cell cycle arrest 2.13004
PRR3 Proline rich 3 Zinc ion binding
Metal ion binding
2.09132





LAMA4 Laminin, alpha 4 Receptor binding 2.03249




ZNF34 Zinc finger protein 34 Zinc ion binding
Metal ion binding
2.02091




ZBTB24 Zinc finger and BTB domain containing 24 Metal ion binding 3.76108
ZBTB24 Zinc finger and BTB domain containing 24 Metal ion binding 3.5799
ARHGAP11B Rho GTPase activating protein 11B Signal transduction 2.5269
ALS2 Amyotrophic lateral sclerosis 2 (juvenile) Response to oxidative stress 2.52641
TRSPAP1 tRNA selenocysteine-associated protein 1 Protein binding 2.43763
MARS2 Methionyl-tRNA synthetase 2, mitochondrial Mitochondrion
Mitochondrial matrix
2.36375
FST Follistatin Negative regulation of cell differentiation 2.34739
SETX Senataxin ATP binding
Cell death
2.30816
PARG Poly (ADP-ribose) glycohydrolase Response to DNA damage stimulus 2.27345
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Nisin-mediated effects on cell apoptosis are
blocked by suppressing CHAC1
To functionally determine whether nisin effects on
HNSCC cell apoptosis and proliferation were mediated by
CHAC1, CHAC1 levels were suppressed in the context of
nisin treatment. CHAC1 suppression with siRNA reversed
the nisin-mediated effects on cell apoptosis, and therefore
decreased HNSCC cell apoptosis upon nisin treatment
compared with controls (Fig. 4). However, CHAC1 sup-
pression did not affect the nisin-mediated effects on
HNSCC cell proliferation and calcium influx levels. Thus,
CHAC1, in part, mediates the nisin effects on HNSCC
cell apoptosis, and these CHAC1-mediated effects are
independent of calcium influxes.
Nisin-mediated effects on cell apoptosis are
enhanced by CHAC1 overexpression
To further confirm that nisin-mediated effects on HNSCC
cell apoptosis are mediated by CHAC1, CHAC1 over-
expression was examined in the context of nisin treatment
(Fig. 5). CHAC1 overexpression enhanced nisin’s effects
on cell apoptosis without affecting cell proliferation and
calcium influx levels. Taken in aggregate, these data indi-
cate that nisin mediates its effects on HNSCC cell apopto-
sis via CHAC1, and CHAC1 functions independent of
calcium influxes.
Nisin reduces HNSCC tumor burden in vivo
Given nisin’s in vitro effects on enhancing apoptosis and
blocking cell proliferation in HNSCC cells, nisin’s in vivo
effects were next examined using a floor-of-mouth oral
cancer xenograft mouse model. Given that nisin doses of
approximately 80 mg/kg did not exhibit adverse effects in
rats [21], we tested a 150 mg/kg dose of nisin administered
over the course of 3 weeks and did not observe adverse
effects in mice, which exhibited normal weight gain and
normal organ histology (Fig. S1A).
In initial experiments, tumors were first established
after approximately 3 weeks following tumor cell inocula-
tion, then tumor-bearing mice were equally distributed
into two groups and nisin or water/control was adminis-
tered to mice via daily oral gavage for 3 weeks. Mice that
received nisin treatment exhibited statistically significant
reduced tumor volumes compared with controls (Fig. 6).
In the next set of experiments, where mice were treated
with nisin or water/control by oral gavage for 3 weeks
prior to and 3 weeks after tumor cell inoculation, nisin
pretreatment again resulted in statistically significant
reduction in tumor volumes (Fig. S1B).
CHAC1 stable suppression reduces tumor
burden in vivo
As in the in vitro data, CHAC1 suppression was next
examined in the in vivo floor-of-the-mouth mouse
model. Mice inoculated with HNSCC cells exhibiting sta-
ble CHAC1 suppression and treated with nisin exhibited
statistically significant increased tumor volumes compared
with controls, indicating that nisin effects are mediated
via CHAC1 in vivo (Fig. 7). CHAC1 suppression alone
had no statistically significant effects on tumor volumes.
In agreement with other in vivo data, nisin treatment
again reduced overall tumor burden compared with the
nonnisin-treated groups.
Discussion
These data demonstrate that nisin induces preferential
apoptosis and decreased cell proliferation in HNSCC cells
compared with primary keratinocytes due to increases in
intracellular calcium, induction of cell cycle arrest, and
Table 1. Continued.
Symbol Description Gene ontology Fold change
KCTD1 Potassium channel tetramerization domain containing 1 Voltage-gated potassium channel activity
Protein binding
Potassium ion transport
Voltage-gated potassium channel complex
Membrane
2.26108
PPAN Peter pan homolog (Drosophila) Protein binding 2.2312
ZNF718 Zinc finger protein 718 Zinc ion binding
Metal ion binding
2.1316
MED13 Mediator complex subunit 13 Receptor activity
Transcription
2.11608
CCNT2 Cyclin T2 Cell cycle
Cell division
2.01302
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activation of CHAC1 in HNSCC cells. Furthermore, nisin
similarly prevents and inhibits the growth of HNSCC
tumors in vivo via induction of CHAC1 expression, as its
suppression significantly increases tumor volume. CHAC1
is a known cation transport regulator and apoptosis
mediator; however, its effects on cancer cell apoptosis
have never been examined. Our studies are, therefore, the
first to report this important new role for CHAC1 in this
process. Future studies will help determine the potential
use of CHAC1 as an adjunctive therapeutic target for
HNSCC.
Calcium influx inhibitors have been known to alter
tumorigenic properties. Nifedipine, a calcium channel
blocker, that inhibits the influx of intracellular calcium
ions within vascular smooth muscle and protects against
angina and hypertension, reduces HNSCC cell migration
[25]. In a recent Phase I clinical trial, a novel calcium
influx inhibitor, carboxyamidotriazole, was shown to sta-
bilize tumor progression in approximately 50% of
patients with advanced disease with low toxicity, indicat-
ing the potential use of calcium influx inhibitors in man-





































Figure 6. Nisin administration reduces HNSCC tumor burden in mice. (A) Mice were injected with UM-SCC-17B cells then administered either
water (CTRL) or nisin (200 mg/kg per day) for 3 weeks. Left panels show superficial tumors, middle panels show dissected tumors, and right
panels show dissected and isolated tumors. (B) Tumor volumes for mice injected with UM-SCC-17B cells and administered either water (CTRL) or












































Figure 7. CHAC1 downregulation counteract the tumor-suppressive effects of nisin in vivo. (A) Top, immunoblots show CHAC1 levels after
stable CHAC1 suppression using lentiviral particles (CTRL shRNA or CHAC1-shRNA) in UM-SCC-17B cells. Bottom, images show the dissected
tumors of mice injected with CTRL shRNA or CHAC1-shRNA and administered either water (CTRL) or nisin (200 mg/kg per day) for 3 weeks.
(B) Tumor volumes for mice injected with CTRL shRNA or CHAC1-shRNA and administered water (CTRL) or nisin (200 mg/kg per day) for
3 weeks. P values for each data set are indicated individually.
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can also inhibit the proliferation, migration, and invasive
potential of HNSCC cells in vitro plus their production
of MMP-2 and MMP-2 [27]. Maslinic acid, a triterpenoid
found in high concentration in olives, induces calcium
influxes that lead to apoptosis of salivary gland adenoid
cystic carcinoma [28]. Thus, the current findings are in
agreement with these and other studies demonstrating
that increased calcium influxes regulate several tumor cell
properties that can be abrogated with the use of calcium
influx inhibitors.
The mechanistic basis of nisin’s selectivity for HNSCC
cells versus primary keratinocytes may stem from the
known structural differences in plasma membrane com-
position between these two cell types. Specifically, the
phospholipid/lipoprotein content and composition of
HNSCC/OSCC cells is known to be functionally different
from that of primary keratinocytes [10–15]. Furthermore,
in preliminary Affymetrix gene array data, nisin treatment
of HNSCC cells showed a preponderance of altered genes
that regulate calcium/ions and lipid/membrane function.
The most highly upregulated gene was CHAC1, a cation
transport regulator that promotes apoptosis and is acti-
vated by oxidized phospholipids. As nisin is known to
preferentially interact with and alter membrane phospho-
lipids, especially phosphatidylcholine, it is possible that
CHAC1 is a downstream nisin target that responds to
alterations in membrane phospholipids. It remains to be
determined what the contribution of phospholipid com-
position is to nisin-mediated effects in this process.
This is the first time that an antibacterial food preser-
vative agent has been shown to effectively reduce and pre-
vent tumorigenic properties in vitro and in vivo. As nisin
is already safely consumed by humans and is approved by
the FDA and WHO for human consumption, nisin lends
itself to a natural transition as an OSCC therapeutic.
Determining the optimal therapeutic dose for treatment
of human OSCC is the next critical step in its validation
process.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Nisin treatment does not alter liver and kidney
histological morphology and preloading with nisin
reduces tumor volume. (A) Representative hematoxylin
and eosin staining of liver and kidney tissue sections from
mice administered 150 mg/kg per day of nisin for
3 weeks (n = 3 mice). (B) Tumor volumes for mice
administered water (CTRL) or nisin (200 mg/kg per day)
for 3 weeks pre- and postinjection of UM-SCC-17B cells.
P values for each data set are indicated individually.
Figure S2. Nisin inhibits Cdc2 phosphorylation but pro-
motes PARP and caspase-3 cleavage. Immunoblots show-
ing (A) Cdc2 and p-Cdc2 and (B) active/cleaved PARP
and caspase-3 expression in control (CTRL) and nisin-
treated UM-SCC-17B cells. b-Actin served as a loading
control.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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